Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
17 oct. 2024 16h30 HE
|
Profound Medical Corp.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
16 oct. 2024 16h15 HE
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain
15 oct. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the...
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT
08 oct. 2024 02h45 HE
|
Hofseth Biocare ASA
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel...
Préparez-vous au décollage : Movember s'associe à l'une des moustaches les plus reconnaissables du Canada pour s'attaquer à la santé masculine
01 oct. 2024 09h00 HE
|
Movember Canada
TORONTO, 01 oct. 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) sont de retour à l'occasion de la campagne la plus poilue du Canada, le 1er Novembre! Cette année, Movember est fier de s'associer à...
Get Ready for Liftoff: Movember Joins Forces with One of Canada’s Most Recognizable Moustaches to Take on Men’s Health
01 oct. 2024 09h00 HE
|
Movember Canada
TORONTO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) are back as Canada’s hairiest campaign returns on Movember 1! This year, Movember is proud to be partnering with Olympian and...
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
01 oct. 2024 07h45 HE
|
Curium
Curium partners with PeptiDream for clinical development, regulatory filing, and commercialization of prostate cancer therapies in Japan.
Oncology Collaboration and Licensing Agreements Analysis Report 2024: SEC-Linked Oncology Contract Documents Reveal In-Depth Deal Structures and Payment Clauses
30 sept. 2024 05h03 HE
|
Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offeringThe report provides access to deal...
Prostate Cancer in the United States: Key Insights into Treatment Awareness & Satisfaction - Make Informed, Strategic Decisions, Identify Opportunities, and Understand Potential Challenges
26 sept. 2024 04h15 HE
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...
Koelis Announces New Compact 3D Probe to Improve Workflow and Reprocessing
25 sept. 2024 09h07 HE
|
Koelis
Koelis is pleased to announce the introduction of our new 3D ultrasound probe that maximizes auto reprocessing compatibility.